Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
Public ClinicalTrials.gov record NCT05521022. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02
Study identification
- NCT ID
- NCT05521022
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Attralus, Inc.
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- AT-02 Drug
- AT-02 (Placebo) Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2022
- Primary completion
- Feb 28, 2025
- Completion
- Feb 28, 2025
- Last update posted
- Apr 2, 2024
2022 – 2025
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Midwest Heart and Vascular | Overland Park | Kansas | 66211 | Recruiting |
| Johns Hopkins | Baltimore | Maryland | 21287 | Recruiting |
| St. Luke's Hospital of Kansas City | Kansas City | Missouri | 64111 | Recruiting |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Recruiting |
| OHSU (Oregon Health & Science University) | Portland | Oregon | 97239 | Recruiting |
| Penn Presbyterian Medical Center | Philadelphia | Pennsylvania | 19104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05521022, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2024 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05521022 live on ClinicalTrials.gov.